uplizna
uplizna: developed by 2 companies · 1 FDA decision. Updated within the last hour.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Horizon Therapeutics Public Ltd Co (HZNP) | Approved |
| Viela Bio, Inc. (VIE) | Approved |
FDA Decisions
Frequently asked questions
Who is developing uplizna?
uplizna is being developed by Horizon Therapeutics Public Ltd Co, Viela Bio, Inc..
What is uplizna's latest FDA decision?
The most recent tracked FDA decision for uplizna is Approval for 1 INDICATIONS AND USAGE UPLIZNA is a CD19-directed cytolytic antibody indicated for the treatment of: Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) Immunoglobulin G4-related disease (IgG4-RD) in adult patients. ( 1.2 ) Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. ( 1.2 ) 1.1 Neuromyelitis Optica Spectru, dated June 11, 2020.
Get deeper analysis on uplizna
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis